Serina Therapeutics Entered into a Merger Agreement with AgeX Therapeutics to Advance its CNS Pipeline Assets
- Serina will merge with a wholly-owned subsidiary of AgeX, and stockholders of Serina will receive shares of AgeX common stock, the transaction is expected to close in Q1’24. Pre-merger AgeX stockholders are expected to own ~25% of the newly combined company while pre-merger Serina stockholders are expected to own ~75%
- The combined company will operate under Serina Therapeutics & common stock is expected to trade on NYSE American under the "SER" ticker. The combined company focuses on advancing Serina’s pipeline of small molecule drug candidates targeting CNS using the POZ Platform
- Advancing pre-clinical studies of Serina’s SER-252 for advanced Parkinson’s disease with an expected submission of IND application to the US FDA to initiate the P-I trial in Q4’24. The combined company will advance Serina’s lipid nanoparticles & ADC by collaborating with other partners
Ref: Businesswire | Image: AgeX Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.